Colton Groome Financial Advisors LLC Boosts Stock Holdings in Stryker Co. (NYSE:SYK)

Colton Groome Financial Advisors LLC raised its holdings in shares of Stryker Co. (NYSE:SYK) by 10.6% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 826 shares of the medical technology company’s stock after purchasing an additional 79 shares during the period. Colton Groome Financial Advisors LLC’s holdings in Stryker were worth $247,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Freedom Wealth Alliance LLC purchased a new position in shares of Stryker in the 4th quarter worth approximately $26,000. Farmers & Merchants Trust Co of Chambersburg PA grew its position in shares of Stryker by 203.3% in the 4th quarter. Farmers & Merchants Trust Co of Chambersburg PA now owns 91 shares of the medical technology company’s stock worth $27,000 after buying an additional 61 shares during the last quarter. Quarry LP purchased a new position in shares of Stryker in the 1st quarter worth approximately $27,000. HBC Financial Services PLLC purchased a new position in shares of Stryker in the 4th quarter worth approximately $37,000. Finally, Bourgeon Capital Management LLC purchased a new position in shares of Stryker in the 4th quarter worth approximately $37,000. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Insider Buying and Selling

In related news, Director Allan C. Golston sold 3,273 shares of the business’s stock in a transaction on Friday, February 2nd. The shares were sold at an average price of $341.00, for a total value of $1,116,093.00. Following the completion of the sale, the director now owns 14,242 shares of the company’s stock, valued at approximately $4,856,522. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other news, Director Allan C. Golston sold 3,273 shares of the company’s stock in a transaction on Friday, February 2nd. The shares were sold at an average price of $341.00, for a total transaction of $1,116,093.00. Following the completion of the sale, the director now owns 14,242 shares of the company’s stock, valued at $4,856,522. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Ronda E. Stryker sold 201,146 shares of the company’s stock in a transaction on Monday, February 5th. The stock was sold at an average price of $342.90, for a total transaction of $68,972,963.40. Following the sale, the director now directly owns 3,755,128 shares of the company’s stock, valued at approximately $1,287,633,391.20. The disclosure for this sale can be found here. In the last quarter, insiders sold 212,109 shares of company stock valued at $72,845,768. 5.90% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on SYK. Wells Fargo & Company lifted their price objective on shares of Stryker from $336.00 to $364.00 and gave the stock an “overweight” rating in a research report on Wednesday, January 31st. Canaccord Genuity Group upgraded shares of Stryker from a “hold” rating to a “buy” rating and lifted their target price for the stock from $315.00 to $360.00 in a research note on Wednesday, January 31st. Citigroup lifted their target price on shares of Stryker from $362.00 to $406.00 and gave the stock a “buy” rating in a research note on Wednesday, April 3rd. Royal Bank of Canada lifted their target price on shares of Stryker from $360.00 to $386.00 and gave the stock an “outperform” rating in a research note on Monday. Finally, TD Cowen lifted their target price on shares of Stryker from $365.00 to $400.00 and gave the stock a “buy” rating in a research note on Thursday, April 11th. Three investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $340.45.

Stryker Stock Performance

Shares of SYK traded down $8.57 during trading hours on Thursday, hitting $327.46. The stock had a trading volume of 2,143,601 shares, compared to its average volume of 1,263,499. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.97 and a current ratio of 1.58. The firm has a 50-day moving average price of $350.57 and a 200 day moving average price of $312.03. Stryker Co. has a fifty-two week low of $249.98 and a fifty-two week high of $361.41. The firm has a market capitalization of $124.59 billion, a price-to-earnings ratio of 39.89, a PEG ratio of 2.72 and a beta of 0.89.

Stryker (NYSE:SYK) last posted its earnings results on Tuesday, January 30th. The medical technology company reported $3.46 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.27 by $0.19. Stryker had a net margin of 15.44% and a return on equity of 22.99%. The firm had revenue of $5.82 billion during the quarter, compared to analysts’ expectations of $5.60 billion. During the same period in the previous year, the business posted $3.00 EPS. The business’s revenue was up 11.8% compared to the same quarter last year. As a group, research analysts anticipate that Stryker Co. will post 11.86 EPS for the current year.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, April 30th. Investors of record on Friday, March 29th will be issued a $0.80 dividend. This represents a $3.20 annualized dividend and a yield of 0.98%. The ex-dividend date is Wednesday, March 27th. Stryker’s payout ratio is presently 38.79%.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.